Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 22,367 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
Interventions
Decitabine, Vorinostat, Vincristine, Dexamethasone, Mitoxantrone, Pegaspargase, Methotrexate
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
25
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 20 more
Conditions
Atopic Dermatitis
Interventions
SB414 2%, SB414 6%, Vehicle
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
9
States / cities
Coral Gables, Florida • Sweetwater, Florida • Boise, Idaho + 6 more
Conditions
Hematologic Malignancies, Graft-Versus-Host Disease
Interventions
Activated PTCy-MILs
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Recurrent Adult Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Laboratory Biomarker Analysis, Temsirolimus
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma
Interventions
PS-341, Thalidomide, Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Type 1 Diabetes Mellitus
Interventions
heart rate Control to Range System (hrCTR) using DiAs Platform, DiAs Control-to-Range System not informed for heart rate
Device · Other
Lead sponsor
Marc Breton
Other
Eligibility
12 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Conditions
CLL, SLL, CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Treatment Free Observation
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Monroe, North Carolina • Philadelphia, Pennsylvania
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Completed Not applicable Interventional Accepts healthy volunteers

Cerebral Responses to Insulin Induced Hypoglycemia

NCT02747680
Conditions
Type 1 Diabetes, Healthy, Hypoglycemia Unawareness
Interventions
hypoglycemia (low blood sugar) in MRI
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Asthma
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more
Completed Not applicable Interventional Accepts healthy volunteers

Aromatherapy for Upper Respiratory Health

NCT06190379
Conditions
Immune System
Interventions
Essential oil blend, Placebo
Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
20 Years to 65 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Franklin, Tennessee
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
anti-CD45 monoclonal antibody AHN-12, yttrium Y 90 anti-CD45 monoclonal antibody AHN-12
Biological · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Asthma, Wheezing
Interventions
Broncho-Vaxom (BV), Placebo
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
6 Months to 18 Months
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Tucson, Arizona • Oakland, California + 8 more
Conditions
Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Acute Undifferentiated Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Cytarabine, Echocardiography Test, Filgrastim, Fludarabine, Hematopoietic Cell Transplantation, Idarubicin, Multigated Acquisition Scan, Pheresis, Total-Body Irradiation, Biospecimen Collection
Drug · Procedure · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Conditions
GATA2, Immunodeficiency
Interventions
Mycophenolate Mofetil, Tacrolimus, Post-Transplant Cyclophosphamide, Total Body Irradiation, Hematopoietic Cell Transplant, Briquilimab, Cyclophosphamide, Fludarabine, Bone Marrow Biopsy, Bone Marrow Aspirate, 2D echo, EKG, PFT's, CT scan of chest, abdomen and pelvis
Drug · Radiation · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Not listed No phase listed Observational Accepts healthy volunteers

Project Baseline Health Study

NCT03154346
Conditions
All
Interventions
Not listed
Lead sponsor
Baseline Study LLC
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
5
States / cities
South San Francisco, California • Stanford, California • Westlake Village, California + 2 more
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG/ABC/3TC FDC DISPERSIBLE TABLET, EPZICOM (ABC/3TC), TIVICAY (DTG)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Multiple Sclerosis
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Theodore R. Brown, MD MPH
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Kirkland, Washington
Conditions
Plasmacytoma, POEMS Syndrome
Interventions
Dexamethasone, Ixazomib Citrate, Lenalidomide, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Asthma
Interventions
Montelukast 5-mg orally added to standard therapy
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 14 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Conditions
Rheumatoid Arthritis
Interventions
SAR153191 (REGN88)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
75
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 66 more
Conditions
Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Interventions
DEN4 Vaccine Candidate, DEN4 Vaccine Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Active, not recruiting No phase listed Observational

Investigating the Impact of Proactive Palliative Care

NCT03667378
Conditions
Metastatic Solid Tumor Cancers, Locally Advanced Solid Tumor Cancers
Interventions
Expectations Survey (CanCORS), Values Survey (Serious Illness Care Program), Functional Assessment of Cancer Therapy-General (FACT-G), NCCN Distress Thermometer, Hospital Anxiety and Depression Scale (HADS), Quality of Communication (QOC), visits with a supportive care clinician
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York